Mazdutide Achieves 20% Weight Loss in Phase 3 Obesity Trial, Innovent Plans China NDA Submission

Innovent Biologics Inc. announced that its Phase 3 clinical trial of mazdutide, a dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, in Chinese adults with obesity (GLORY-2) met both its primary and all key secondary endpoints. Mazdutide 9 mg achieved up to 20.1% weight loss in obese adults without type 2 diabetes after one year of treatment using a 2-step dose titration. Innovent plans to submit a new drug application (NDA) for mazdutide 9 mg for weight management to the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) in the near term. Clinical findings on mazdutide have already been published in international journals such as The New England Journal of Medicine, Nature Communications, Diabetes Care, and eClinicalMedicine, and have been presented at scientific conferences including those of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN28678) on November 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)